Literature DB >> 4029252

Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis.

H P Hoensch, K Balzer, P Dylewizc, W Kirch, H Goebell, E E Ohnhaus.   

Abstract

Six patients with primary biliary cirrhosis (PBC) were treated with a daily oral dose of 600 mg rifampicin for 2 weeks to induce the hepatic metabolism of drugs and bile acids. On rifampicin 5 of 6 patients experienced a pronounced decrease of their pruritus. In all patients the oxidative cytochrome P-450 dependent drug metabolism was induced as shown by an increase of antipyrine-clearance from 36.3 +/- 8.8 to 80.6 +/- 20.1 ml/min and an enhanced urinary excretion of 6-beta-hydroxycortisol from 454 +/- 1.99 to 1607 +/- 362 micrograms/24 h. Furthermore, in all 6 patients the serum alkaline phosphatase declined. In the 3 cholestatic patients (bilirubin greater than 1.0 mg/dl) the serum concentration of total and conjugated bile acids was strikingly reduced. Thus, rifampicin is an inducer of hepatic metabolism in PBC-patients, ameliorates the pruritus and can lower serum concentrations of alkaline phosphatase and bile acids.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4029252     DOI: 10.1007/bf00544371

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  A simple and sensitive assay of total serum bile acids.

Authors:  F Mashige; K Imai; T Osuga
Journal:  Clin Chim Acta       Date:  1976-07-01       Impact factor: 3.786

2.  Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers.

Authors:  M Danhof; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

3.  Enzyme-inducing drug combinations and their effects on liver microsomal enzyme activity in man.

Authors:  E E Ohnhaus; E Gerber-Taras; B K Park
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 4.  Metabolism and pharmacokinetics of the antibiotic rifampin.

Authors:  M T Kenny; B Strates
Journal:  Drug Metab Rev       Date:  1981       Impact factor: 4.518

5.  Phenobarbital treatment in primary biliary cirrhosis. Differences in bile acid composition between responders and nonresponders.

Authors:  F Stellaard; M G Bolt; J L Boyer; P D Klein
Journal:  J Lab Clin Med       Date:  1979-12

6.  Phenobarbital effects in cholestatic liver diseases.

Authors:  J R Bloomer; J L Boyer
Journal:  Ann Intern Med       Date:  1975-03       Impact factor: 25.391

Review 7.  Clinical pharmacokinetics of rifampicin.

Authors:  G Acocella
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

8.  Phenobarbital-induced alterations of bile acid metabolism in cases of intrahepatic cholestasis.

Authors:  P Back
Journal:  Klin Wochenschr       Date:  1982-06-01

9.  Effects of rifampin on biliary lipids in humans.

Authors:  K von Bergmann; J Fierer; H Y Mok; S M Grundy
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

10.  Enzyme induction and renal function in man.

Authors:  E E Ohnhaus; J Martin; J Kinser; J P Colombo
Journal:  Br J Clin Pharmacol       Date:  1977-02       Impact factor: 4.335

  10 in total
  13 in total

1.  Rifampicin Induces Bicarbonate-Rich Choleresis in Rats: Involvement of Anion Exchanger 2.

Authors:  Wei Wang; Xiaofei Ren; Yi Cai; Lihong Chen; Weiping Zhang; Jianming Xu
Journal:  Dig Dis Sci       Date:  2015-08-29       Impact factor: 3.199

Review 2.  Intrahepatic cholestasis of pregnancy.

Authors:  Victoria Geenes; Catherine Williamson
Journal:  World J Gastroenterol       Date:  2009-05-07       Impact factor: 5.742

3.  Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients.

Authors:  P B Watkins; S A Murray; L G Winkelman; D M Heuman; S A Wrighton; P S Guzelian
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

4.  Primary biliary cirrhosis in the mouse: induction by human mycoplasma-like organisms.

Authors:  L Johnson; E Wirostko; W Wirostko
Journal:  Int J Exp Pathol       Date:  1990-10       Impact factor: 1.925

5.  Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis.

Authors:  S Teng; M Piquette-Miller
Journal:  Br J Pharmacol       Date:  2007-04-16       Impact factor: 8.739

Review 6.  Hepatic disorders. Features and appropriate management.

Authors:  M A Aldersley; J G O'Grady
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

Review 7.  Treatment of pruritus associated with systemic disorders in the elderly: a review of the role of new therapies.

Authors:  Ann Lonsdale-Eccles; Andrew J Carmichael
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 8.  The pregnane X receptor: from bench to bedside.

Authors:  Xiaochao Ma; Jeffrey R Idle; Frank J Gonzalez
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-07       Impact factor: 4.481

Review 9.  Clinical features and management of primary biliary cirrhosis.

Authors:  Andrea Crosignani; Pier-Maria Battezzati; Pietro Invernizzi; Carlo Selmi; Elena Prina; Mauro Podda
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

Review 10.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Authors:  M M Galteau; F Shamsa
Journal:  Eur J Clin Pharmacol       Date:  2003-11-06       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.